{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:31:31Z","timestamp":1759624291324,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":798,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K21284"],"award-info":[{"award-number":["JP16K21284"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26461429"],"award-info":[{"award-number":["26461429"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.exphem.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:48:12Z","timestamp":1583714892000},"page":"45-53.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-2876","authenticated-orcid":false,"given":"Yoshiaki","family":"Chinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Maegawa-Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Matsumura-Kimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Takimoto-Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuna","family":"Tanba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Fujibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Kuwahara-Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.02.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/475731","article-title":"Before it gets started: regulating translation at the 5\u2032 UTR","volume":"2012","author":"Araujo","year":"2012","journal-title":"Comp Funct Genomics"},{"key":"10.1016\/j.exphem.2020.02.004_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrm2838","article-title":"The mechanism of eukaryotic translation initiation and principles of its regulation","volume":"11","author":"Jackson","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1101\/gr.GR-1460R","article-title":"CART classification of human 5\u2032 UTR sequences","volume":"10","author":"Davuluri","year":"2000","journal-title":"Genome Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0004","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/0008-5472.CAN-07-5635","article-title":"Targeting the eukaryotic translation initiation factor 4E for cancer therapy","volume":"68","author":"Graff","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0005","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/sj.onc.1207549","article-title":"eIF4E\u2013from translation to transformation","volume":"23","author":"Mamane","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2015-12-685156","article-title":"Shooting the messenger (RNA) in B-cell lymphoma","volume":"127","author":"Yeomans","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0007","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2009-09-220020","article-title":"Targeting the translational machinery as a novel treatment strategy for hematologic malignancies","volume":"115","author":"Hagner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0008","first-page":"1369","article-title":"A cis-acting element in the BCL-2 gene controls expression through translational mechanisms","volume":"12","author":"Harigai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcdb.2004.11.006","article-title":"The implications of structured 5\u2032 untranslated regions on translation and disease","volume":"16","author":"Pickering","year":"2005","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1357-2725(98)00133-2","article-title":"Translational control of growth factor and proto-oncogene expression","volume":"31","author":"Willis","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8","article-title":"Translational control of the proteome: relevance to cancer","volume":"1","author":"Dua","year":"2001","journal-title":"Proteomics"},{"key":"10.1016\/j.exphem.2020.02.004_bib0012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/5082","article-title":"Mutation of the CDKN2A 5\u2032 UTR creates an aberrant initiation codon and predisposes to melanoma","volume":"21","author":"Liu","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2020.02.004_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4161\/rna.8.1.14260","article-title":"Effect of mutations on the p53 IRES RNA structure: implications for de-regulation of the synthesis of p53 isoforms","volume":"8","author":"Grover","year":"2011","journal-title":"RNA Biol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0014","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1158\/0008-5472.CAN-11-3549","article-title":"Proteomic identification of a direct role for cyclin d1 in DNA damage repair","volume":"72","author":"Jirawatnotai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0015","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0016","first-page":"1201","article-title":"Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma","volume":"33","author":"Kuroda","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0017","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2020.02.004_bib0018","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1101\/gad.1586007","article-title":"Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication","volume":"21","author":"Aggarwal","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2020.02.004_bib0019","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/ol.2011.404","article-title":"Impaired nuclear export of tumor-derived C-terminal truncated cyclin D1 mutant in ESCC cancer","volume":"2","author":"Hao","year":"2011","journal-title":"Oncol Lett"},{"key":"10.1016\/j.exphem.2020.02.004_bib0020","doi-asserted-by":"crossref","first-page":"628","DOI":"10.15252\/emmm.201404242","article-title":"Consequence of the tumor-associated conversion to cyclin D1b","volume":"7","author":"Augello","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.exphem.2020.02.004_bib0021","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0022","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2402817","article-title":"Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing B-malignancies: relevance for the pathogenesis","volume":"17","author":"Rou\u00e9","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.02.004_bib0023","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.21166","article-title":"Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1","volume":"117","author":"Sander","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2020.02.004_bib0024","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/sj.onc.1210857","article-title":"Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA","volume":"27","author":"Chinen","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0025","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/1535-7163.MCT-12-0605","article-title":"RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma","volume":"11","author":"Shimura","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2020.02.004_bib0026","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.02.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/686984","article-title":"mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions","volume":"2014","author":"Showkat","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.exphem.2020.02.004_bib0028","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1038\/sj.onc.1209888","article-title":"mTOR, translation initiation and cancer","volume":"25","author":"Mamane","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0029","doi-asserted-by":"crossref","first-page":"e4732","DOI":"10.1371\/journal.pone.0004732","article-title":"A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis","volume":"4","author":"He","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2020.02.004_bib0030","article-title":"The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression","volume":"2","author":"Shilo","year":"2014","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0031","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.02.004_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2013.570","article-title":"Alternative splicing in cancer: implications for biology and therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0033","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1471-2164-12-505","article-title":"Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis","volume":"12","author":"Thorsen","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.exphem.2020.02.004_bib0034","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/leu.2009.31","article-title":"t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals","volume":"23","author":"Lecluse","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.02.004_bib0035","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2020.02.004_bib0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.beha.2012.03.001","article-title":"Flipping the cyclin D1 switch in mantle cell lymphoma","volume":"25","author":"Hasanali","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2020.02.004_bib0037","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2007-11-119362","article-title":"Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma","volume":"112","author":"Z\u00f6llinger","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0038","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0039","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1038\/sj.onc.1205923","article-title":"Role of the phosphatidylinositol 3-kinase\/Akt and mTOR\/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma","volume":"21","author":"Pene","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.02.004_bib0040","first-page":"6763","article-title":"The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses","volume":"60","author":"Tu","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0041","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1158\/0008-5472.CAN-14-1420","article-title":"Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma","volume":"74","author":"Chinen","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2020.02.004_bib0042","doi-asserted-by":"crossref","first-page":"39185","DOI":"10.18632\/oncotarget.16642","article-title":"PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1\/C2 inhibitor PP242","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2020.02.004_bib0043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.02.004_bib0044","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2020.02.004_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/bj20031027","article-title":"Regulation of protein synthesis by eIF4E phosphorylation in adult cardiocytes: the consequence of secondary structure in the 5\u2032-untranslated region of mRNA","volume":"378","author":"Jr","year":"2004","journal-title":"Biochem J"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2030103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2030103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:35:10Z","timestamp":1759566910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2030103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"alternative-id":["S0301472X2030103X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.02.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}